|Articles|January 11, 2023
- Pharmaceutical Executive: January 2023
- Volume 43
- Issue 01
What We Foresee in ’23: Pharm Exec’s Annual Industry Outlook
Exploring the most relevant topics affecting the biopharma industry as the new year gets underway—ranging from trends ripe with risk and opportunity to those driving more definitive growth opportunities in patient care.
Advertisement
Articles in this issue
about 3 years ago
Key Factors Attributing to a Successful Product Launchabout 3 years ago
Closing the Digital Gap: FDA’s Oversight of Social Mediaabout 3 years ago
Sales-Rep Compensation: Adding Long-Term Incentives to Mixabout 3 years ago
Co-creating New Innovationsabout 3 years ago
The Potential Impact of the IRAabout 3 years ago
Patient Hubs Continue Growthabout 3 years ago
Social Media’s Complex Climbabout 3 years ago
Industry Workforce Seeks Clarityabout 3 years ago
Cybersecurity Threats & PharmaNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Your Phase III Clinical Protocol Is Your Initial Product Launch
2
Pharmaceutical Executive Daily: Public Citizen Sues The Trump Administration Over Undisclosed Drug Price Agreements
3
What AI Trends Did You See at the 2026 JP Morgan Healthcare Conference?
4
AstraZeneca Enters $4.7 Billion Collaboration Agreement with CSPC Pharmaceuticals
5